Ozempic and Wegovy Price Drop 2027: What It Means for Patients
Novo Nordisk announced a 50% list price cut on Wegovy and 35% on Ozempic, effective January 2027. Here is what that means, who benefits, and how to get the lowest price now.
On February 24, 2026, Novo Nordisk announced something that would have seemed unlikely two years ago: a major price cut on its entire semaglutide portfolio - Wegovy, Ozempic, and Rybelsus - all dropping to $675 per month effective January 1, 2027.
For Wegovy, that is roughly a 50% reduction from the current list price. For Ozempic, about 35%.
Here is what you need to know and what you can do right now.
What exactly was announced?
Novo Nordisk confirmed that effective January 1, 2027:
- Wegovy (semaglutide injection 2.4 mg and tablets 25 mg): list price reduced to $675/month - all doses
- Ozempic (semaglutide injection 0.5 mg, 1 mg, 2 mg): list price reduced to $675/month - all doses
- Rybelsus (semaglutide tablets 7 mg, 14 mg): list price reduced to $675/month
The company framed this as a move to improve access, particularly for patients whose out-of-pocket costs are directly linked to the list price - such as those with high-deductible health plans or co-insurance benefit designs.
Why is this happening?
Several converging pressures:
Competition. Orforglipron (Eli Lilly's oral GLP-1 pill) is pending FDA approval and is expected to launch at a lower price point. CagriSema, also from Novo Nordisk, will compete with Wegovy. If prices do not come down, patients will switch.
Political pressure. GLP-1 drug pricing has been scrutinised in Congress and by health policy advocates. Reducing list prices is a way to manage that pressure.
Telehealth and compounding. Millions of patients were accessing compounded semaglutide at $99–$250/month through platforms like Hims & Hers. As compounding ends, Novo Nordisk needs a competitive price point to retain those patients.
Expanding access. Obesity affects over 100 million Americans. At $1,349/month, most cannot afford long-term treatment. Halving the price dramatically expands the realistic patient population.
Who benefits most from the 2027 price cut?
The reduction in list price directly helps:
- Patients with high-deductible health plans where out-of-pocket costs are a percentage of list price
- Patients with co-insurance benefit designs
- Patients who pay out of pocket entirely
- Medicare Part D patients, where list price affects cost calculations
Patients already on insurance with flat copays may see less change initially.
What about now - before 2027?
You do not have to wait until January 2027 to reduce your cost. Several options are available today:
NovoCare Pharmacy (Novo Nordisk direct)
Self-pay pricing for Wegovy at $499/month through Novo Nordisk's own direct pharmacy at novocare.com. This price does not require insurance.
Hims & Hers and other telehealth platforms
Following the March 2026 agreement, Hims & Hers now offers branded Wegovy and Ozempic at the same NovoCare self-pay prices. Similar pricing is available through Ro, Found, and other platforms.
Insurance prior authorisation
Many plans now cover Wegovy - especially following the 2024 approval for cardiovascular risk reduction. If your plan denied coverage previously, it may be worth reapplying with updated clinical documentation.
LillyDirect (for Zepbound and Mounjaro)
If you are considering switching to tirzepatide, Eli Lilly's LillyDirect platform offers Zepbound single-dose vials at competitive self-pay pricing.
Patient assistance programmes
For patients who genuinely cannot afford medication costs, Novo Nordisk and Eli Lilly both offer patient assistance programmes based on income.
What if I am on Mounjaro or Zepbound?
This announcement specifically covers Novo Nordisk's semaglutide products. Eli Lilly has not yet made equivalent announcements about tirzepatide pricing, though competitive pressure from the semaglutide price cut may prompt a response.
Final takeaway
Wegovy and Ozempic are dropping to $675/month list price in January 2027 - roughly half the current Wegovy price. Patients whose costs are tied to list price will see the most direct benefit. In the meantime, self-pay options through NovoCare and telehealth platforms already offer prices in this range. If access to GLP-1 medication has been a barrier, the landscape is improving significantly.
Consult your healthcare provider about which medication and payment option is right for your situation.
Sources
- Novo Nordisk price reduction announcement, February 24, 2026: drugs.com
- Novo Nordisk / Hims & Hers agreement, March 9, 2026
- NovoCare Pharmacy pricing: novocare.com
- Wegovy FDA approval history: drugs.com/history/wegovy.html
FAQ
How much will Ozempic cost in 2027?
Novo Nordisk announced that Ozempic will be reduced to a list price of $675 per month across all doses, effective January 1, 2027. That represents approximately a 35% reduction from the current list price.
How much will Wegovy cost in 2027?
Wegovy (injection and pill) will also move to a $675 per month list price effective January 1, 2027 - approximately a 50% reduction from the current list price of around $1,349/month.
Does this affect what I pay right now?
Not directly. The list price change takes effect January 1, 2027. However, there are self-pay programmes available now - NovoCare Pharmacy offers Wegovy at $499/month self-pay, and Hims & Hers and other telehealth platforms offer similar pricing following the March 2026 agreement.
Will insurance coverage change?
The list price reduction may improve insurance coverage decisions over time, but it does not automatically change your copay or coverage. Patients whose out-of-pocket costs are directly linked to list price (high-deductible plans, co-insurance) will see the biggest benefit.